Humacyte, Inc.

NASDAQ:HUMA

Biotechnology

Healthcare
$0.50 -3.35%

-$0.03 today

Market cap
$138.90M
Beta
2.46
P/E (TTM)
-1.9
EPS (TTM)
-$0.49
52W Low $0.55High $2.84

Volume 3.91M

Average 8.14M

HUMA Interest Income

Income earned on cash, deposits, and investments held by the company.

Humacyte, Inc.NASDAQ: HUMA

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income declines year over year

Q1 FY2026 interest income of $330K fell 50.2% year over year, behind the -39.6% change in trailing-twelve-month interest income. Sequentially, it fell 34.4% from the prior quarter. Over 3 fiscal years it compounded at -0.5% a year.

Context

  • Interest income amounted to 126.9% of revenue in FY2025.
  • Interest income increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -50.2% toward the trailing-twelve-month pace of -39.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$330K-34.4% QoQ
Last fiscal yearDec 2025
$2.59M-37.0% YoY
LTMMar 2026
$2.26M-39.6% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-50.2%——
1 year-37.0%——
3-year CAGR-0.5%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
2.59M USD
Year-over-year change
-37.0%
4-year CAGR
+256.6%

Interest Income vs competitors

How HUMA compares with its peers on the latest reported figures

  • HUMA's LTM Mar 2026 interest income of $2.26M is the 7th highest of the 11 companies compared; the peer median is $7.44M.
  • Its year-over-year change of -39.6% is the 5th highest of 10, against a peer median of -40.6%.
  • Interest income amounts to 111.9% of revenue for HUMA, versus a peer median of 25.3%.
HUMA Competitors Peer median
Interest Income for HUMA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$14.02M -40.6%+13.7%—
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$13.26M -32.7%—231.0%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$9.27M -47.9%+57.6%20.4%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$9.24M -44.8%+81.0%25.3%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$7.8M -35.9%+15.5%27.6%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$7.08M -30.1%+10.6%—
HUMAHumacyte, Inc.LTM Mar 2026$2.26M -39.6%-0.5%111.9%
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$1.47M -36.4%+95.9%—
SGMTSagimet Biosciences Inc.LTM Mar 2026$800K -90.5%+119.5%—
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$0 ——0.0%
IMRXImmuneering CorporationLTM Mar 2026-$411.45M -18576.2%+44.2%—
Peer median (excluding HUMA) $7.44M-40.6%+50.9%25.3%

Competitors are the stored peer set for HUMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.26M1.57M002.04M
Cost of Revenue61.34M8.26M76.55M7.19M17.05M
Gross Profit(60.08M)(6.69M)(76.55M)(7.19M)(15.01M)
Gross Margin-4756.8%-427.5%——-736.5%
Research & Development61.34M63.26M76.55M88.6M69.3M
Selling, General & Admin21.13M22.88M20.39M25.8M31.17M
Operating Expenses21.13M77.89M23.5M107.21M92.43M
Depreciation & Amortization8.24M8.21M7.72M7.19M7.35M
EBITDA(13.89M)2.45M(96.46M)(132.23M)(22.24M)
EBITDA Margin-1099.6%156.2%——-1091.2%
Operating Income(81.21M)(84.58M)(100.05M)(114.4M)(107.44M)
Operating Margin-6429.8%-5404.3%——-5271.7%
Interest Income16K2.63M5.47M4.1M2.59M
Interest Expense4.35M6.2M6.6M9.28M11.25M
Other Income / Expenses54.73M72.61M(10.73M)(34.3M)66.6M
Income Before Tax(26.48M)(11.97M)(110.78M)(148.7M)(40.83M)
Pre-Tax Margin-2096.4%-764.5%——-2003.6%
Income Tax Expense00000
Net Income(26.48M)(11.97M)(110.78M)(148.7M)(40.83M)
Net Margin-2096.4%-764.5%——-2003.6%
EPS (Basic)(0.66)(0.12)(1.07)(1.26)(0.26)
EPS (Diluted)(0.66)(0.12)(1.07)(1.26)(0.26)
Weighted Avg Shares39.97M103.05M103.42M118.48M158.16M
Weighted Avg Shares (Diluted)39.97M103.05M103.42M118.48M158.16M

Humacyte, Inc.

NASDAQ:HUMA

Intrinsic Alpha fair value

Locked

Current Price

$0.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.